Cefdinir: in vitro activity study and effect of human serum.
Julio Alberto García-Rodríguez, I. Trujillano-Martín, José Elías García‐Sánchez
Abstract
Julio Alberto García-Rodríguez, I. Trujillano-Martín, José Elías García‐Sánchez
Abstract
The in-vitro activity of cefdinir (Cl-983, FK482), an orally absorbed aminothiazole cephalosporin, was compared with that of penicillin, ampicillin, amoxycillin, amoxycillin/clavulanic acid (2/1), cefaclor, cefuroxime, cefixime, cefotaxime, vancomycin and erythromycin against 370 clinical isolates of Gram-negative and Gram-positive bacteria. Cefdinir was highly active against Staphylococcus aureus and S. epidermidis, inhibiting 90% of the strains at doses of 0.25 and 0.5 mg/l respectively. However, cefdinir was not active against methicillin-resistant S. aureus (range 16- > 128 mg/l). The respiratory pathogens Moraxella catarrhalis, Streptococcus pneumoniae, and S. pyogenes were also susceptible (MIC90 < or = 0.5 mg/l), but against Enterococcus spp. cefdinir displayed no useful activity. The common members of the family Enterobacteriaceae were susceptible (MIC90 < or = 1 mg/l), but those possessing chromosomal beta-lactamases were more resistant (MIC90 2-8 mg/l). The presence of human serum had little effect on MICs of cefdinir. These results indicate that cefdinir exhibited a wide spectrum for an oral cephalosporin and support its possible clinical use against susceptible pathogens in infections of the skin, soft tissue, respiratory and urinary tracts.
OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The in-vitro activity of cefdinir (Cl-983, FK482), an orally absorbed aminothiazole cephalosporin, was compared with that of penicillin, ampicillin, amoxycillin, amoxycillin/clavulanic acid (2/1), cefaclor, cefuroxime, cefixime, cefotaxime, vancomycin and erythromycin against 370 clinical isolates of Gram-negative and Gram-positive bacteria. Cefdinir was highly active against Staphylococcus aureus and S. epidermidis, inhibiting 90% of the strains at doses of 0.25 and 0.5 mg/l respectively. However, cefdinir was not active against methicillin-resistant S. aureus (range 16- > 128 mg/l). The respiratory pathogens Moraxella catarrhalis, Streptococcus pneumoniae, and S. pyogenes were also susceptible (MIC90 < or = 0.5 mg/l), but against Enterococcus spp. cefdinir displayed no useful activity. The common members of the family Enterobacteriaceae were susceptible (MIC90 < or = 1 mg/l), but those possessing chromosomal beta-lactamases were more resistant (MIC90 2-8 mg/l). The presence of human serum had little effect on MICs of cefdinir. These results indicate that cefdinir exhibited a wide spectrum for an oral cephalosporin and support its possible clinical use against susceptible pathogens in infections of the skin, soft tissue, respiratory and urinary tracts.
Key concepts: Cefdinir, Cefuroxime, Cefaclor, Microbiology, Cefixime, Cefotaxime, Cephalosporin, Streptococcus pneumoniae